Clinical Trial Update: Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat) [EARLY_Phase 1]

View source ↗

Summary

This early Phase 1 trial update describes characterization of T-cell responses in participants previously treated with atabecestat (JNJ-54861911) for Alzheimer'…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Atabecestat (atabecestat)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Alzheimer Disease | EARLY_Phase 1 | Status: COMPLETED